npj Breast Cancer

Papers
(The H4-Index of npj Breast Cancer is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Biological correlates associated with high-risk breast cancer patients identified using a computational method309
Sequence of therapy impact on older women with comorbidities and triple-negative or HER2-positive breast cancer171
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab169
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer155
Circulating tumor cells in breast cancer: clinical validity and utility143
Reversion of breast epithelial polarity alterations caused by obesity121
Prediction models for hormone receptor status in female breast cancer do not extend to males: further evidence of sex-based disparity in breast cancer101
The deubiquitinating enzyme USP4 regulates BRCA1 stability and function92
Breast cancer survivors’ opinion on personalizing endocrine therapy and developing informative tools88
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer86
The clinical and molecular significance associated with STING signaling in breast cancer74
Current gene panels account for nearly all homologous recombination repair-associated multiple-case breast cancer families69
Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer66
Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?64
IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women63
Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer62
Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study61
UACA locus is associated with breast cancer chemoresistance and survival58
Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-654
C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells54
Subclonal heterogeneity and evolution in breast cancer50
Clinical relevance of pathogenic germline variants in mismatch repair genes in Chinese breast cancer patients49
HBXIP induces anoikis resistance by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis and stabilize Prdx1 in breast cancer49
Publisher Correction: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models49
Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases48
Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy46
Increased trunk fat is associated with altered gene expression in breast tissue of normal weight women44
Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer43
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer42
Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses42
Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer41
Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial39
Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors38
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients38
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial37
ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation37
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape36
0.093139886856079